What is EVAX's current stock price?

EVAX (Evaxion Biotech A/S) is currently trading at $4.08 with a market cap of $25.8M.

What sector is Evaxion Biotech A/S in?

Evaxion Biotech A/S (EVAX) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is EVAX a good stock to buy?

Analysts have a Buy consensus on EVAX with a price target of $9.50. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

EVAX Evaxion Biotech A/S

Healthcare

$4.08+0.49%ClosedMarket Cap: $25.8M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

2.00

P/S

3.42

EV/EBITDA

-0.90

DCF Value

$37.49

FCF Yield

0.0%

Div Yield

0.0%

Margins & Returns

Gross Margin

100.0%

Operating Margin

-122.2%

Net Margin

-129.8%

ROE

-77.9%

ROA

-34.4%

ROIC

-34.0%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$0.00	$-3.6M	$—
Q4 null	$0.00	$-5.9M	$—
FY null	$7.5M	$-7.7M	$—
Q3 null	$7.5M	$4.6M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$9.50

Target (Median)

$9.50

Target Range

$9.00 - $10.00

1 Strong Buy3 Buy0 Hold0 Sell0 Strong Sell

HC Wainwright & Co.Buy

2026-04-24

HC Wainwright & Co.Buy

2026-03-09

Lake StreetBuy

2026-03-09

Lake StreetBuy

2025-10-20

HC Wainwright & Co.Buy

2025-10-20

Trading Activity

Insider Trades

View All

Bitsch-Norhave Jensdirector

SellFri Apr 24

Mattsson Andreas Holmofficer: CAIO Chief AI Officer

SellFri Apr 10

Mattsson Andreas Holmofficer: CAIO Chief AI Officer

SellFri Apr 10

Mattsson Andreas Holmofficer: CAIO Chief AI Officer

SellFri Apr 10

Mattsson Andreas Holmofficer: CAIO Chief AI Officer

SellFri Apr 10

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

0.27

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase IIa trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. The company was incorporated in 2008 and is headquartered in Hørsholm, Denmark.

Peers